Silvia Capellino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Silvia Capellino has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Rainer Hans Straub
Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany
26 shared publications - Paola Montagna
Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital, Genoa, Italy
12 shared publications - Maurizio Cutolo
Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine (DiMI) University of Genova Genoa Italy
11 shared publications Maurizio Cutolo
Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132, Genoa, Italy
7 shared publicationsB Villaggio
6 shared publicationsA Sulli
Department of Internal Medicine, Research Laboratory and Division of Rheumatology, San Martino Hospital, University of Genova, Genova, Italy
5 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2431
Dopamine-Altering Medication Use Is Associated with Immune and Sickness-Related Outcomes: A Sex-Stratified Population-Based Study
Background/Objectives: Dopaminergic signaling regulates immune-cell activity in experimental models, but its association with immune-related outcomes in human populations remains unclear. We examined whether use of dopamine (DA)-altering medications was associated with immune-related symptoms, systemic inflammatory biomarkers, and recent health-related activity limitation. Methods: We analyzed National Health and Nutrition Examination Survey data from 53,585 participants aged 16–65 years. Primary analyses compared users of any DA-altering medication with nonusers. Secondary analyses distinguished medications expected to increase or decrease dopaminergic signaling. Outcomes included self-reported colds, infections, and days of reduced usual activity due to health problems in the preceding 30 days, as well as C-reactive protein (CRP) and white blood cell (WBC) counts. We also conducted sex-stratified and sensitivity analyses. Results: DA-altering medication use was associated with greater odds of recent health-related activity limitation (odds ratio 3.38, 95% confidence interval 2.94–3.90), higher CRP (+40.2%), and higher WBC counts (+4.0%) compared with nonuse. Associations with recent colds and infections were not statistically significant in the overall primary analysis. In secondary analyses, DA-decreasing medication use was associated with lower odds of recent colds among males and higher odds of infections among females, and health-related activity limitation and inflammatory biomarker associations were generally stronger for DA-decreasing medications. Elevated CRP and associations with health-related activity limitation persisted in analyses excluding participants with depressive symptoms and mental health-related activity limitation. Conclusions: DA-altering medication use was associated with systemic inflammatory biomarkers and recent health-related activity limitation. Longitudinal studies are needed to determine whether these associations reflect medication effects, underlying treatment indications, or both.
- 23 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2431
Open AccessDopamine-Altering Medication Use Is Associated with Immune and Sickness-Related Outcomes: A Sex-Stratified Population-Based Study
Background/Objectives: Dopaminergic signaling regulates immune-cell activity in experimental models, but its association with immune-related outcomes in human populations remains unclear. We examined whether use of dopamine (DA)-altering medications was associated with immune-related symptoms, systemic inflammatory biomarkers, and recent health-related activity limitation. Methods: We analyzed National Health and Nutrition Examination Survey data from 53,585 participants aged 16–65 years. Primary analyses compared users of any DA-altering medication with nonusers. Secondary analyses distinguished medications expected to increase or decrease dopaminergic signaling. Outcomes included self-reported colds, infections, and days of reduced usual activity due to health problems in the preceding 30 days, as well as C-reactive protein (CRP) and white blood cell (WBC) counts. We also conducted sex-stratified and sensitivity analyses. Results: DA-altering medication use was associated with greater odds of recent health-related activity limitation (odds ratio 3.38, 95% confidence interval 2.94–3.90), higher CRP (+40.2%), and higher WBC counts (+4.0%) compared with nonuse. Associations with recent colds and infections were not statistically significant in the overall primary analysis. In secondary analyses, DA-decreasing medication use was associated with lower odds of recent colds among males and higher odds of infections among females, and health-related activity limitation and inflammatory biomarker associations were generally stronger for DA-decreasing medications. Elevated CRP and associations with health-related activity limitation persisted in analyses excluding participants with depressive symptoms and mental health-related activity limitation. Conclusions: DA-altering medication use was associated with systemic inflammatory biomarkers and recent health-related activity limitation. Longitudinal studies are needed to determine whether these associations reflect medication effects, underlying treatment indications, or both.
- Open Access
- 1 January 2026
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 33 (1) , 138-149
In vivo Effects of Acute Inflammatory Responses on Dopaminergic Receptor Expression in Leukocytes and Marginal Effects of Hypoxia Pretreatment
Introduction: Lipopolysaccharide (LPS) is widely used to study the mechanisms underlying acute inflammation. Interestingly, several studies suggest that LPS also regulates central dopaminergic signaling. Despite these findings in the brain, the effects of LPS on the dopaminergic system in the periphery remain poorly understood. Notably, peripheral immune cells express dopamine receptors (DRs) and can respond to dopamine. Dysregulation of the dopaminergic system in immune cells has been reported in various chronic inflammatory conditions. Additionally, studies suggest that hypoxia may also modulate dopamine synthesis and potentially amplify LPS-induced effects. Methods: The aim of this study was to investigate the effects of peripheral LPS administration on the dopaminergic system in male human peripheral blood mononuclear cells by measuring dopamine plasma levels and the expression of tyrosine hydroxylase and DRs. Additionally, we explored whether these effects are modulated by prior hypoxic exposure. Results: Our results suggest that in vivo LPS modulates the expression of DRs on monocytes and natural killer cells, as reflected by an upregulation after 24 h. In contrast, the effects of LPS on T and B cells were weaker, with a predominantly inhibitory influence on DR expression, supporting the notion of a cell-specific effect of LPS on dopaminergic signaling within the immune system. Additionally, our results indicate that hypoxic pretreatment did not alter LPS-induced changes in the dopaminergic pathway. Conclusion: Taken together, this study demonstrates for the first time that systemic LPS administration modulates DR expression in male peripheral immune cells. Further, our in vitro findings suggest that it is the LPS-induced immune response, rather than LPS itself, that drives changes in the dopaminergic pathway in specific immune cell subpopulations. However, further research is needed to elucidate the functional relevance of these findings in clinical contexts.
- 1 January 2026
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 33 (1) , 138-149
Open AccessIn vivo Effects of Acute Inflammatory Responses on Dopaminergic Receptor Expression in Leukocytes and Marginal Effects of Hypoxia Pretreatment
Introduction: Lipopolysaccharide (LPS) is widely used to study the mechanisms underlying acute inflammation. Interestingly, several studies suggest that LPS also regulates central dopaminergic signaling. Despite these findings in the brain, the effects of LPS on the dopaminergic system in the periphery remain poorly understood. Notably, peripheral immune cells express dopamine receptors (DRs) and can respond to dopamine. Dysregulation of the dopaminergic system in immune cells has been reported in various chronic inflammatory conditions. Additionally, studies suggest that hypoxia may also modulate dopamine synthesis and potentially amplify LPS-induced effects. Methods: The aim of this study was to investigate the effects of peripheral LPS administration on the dopaminergic system in male human peripheral blood mononuclear cells by measuring dopamine plasma levels and the expression of tyrosine hydroxylase and DRs. Additionally, we explored whether these effects are modulated by prior hypoxic exposure. Results: Our results suggest that in vivo LPS modulates the expression of DRs on monocytes and natural killer cells, as reflected by an upregulation after 24 h. In contrast, the effects of LPS on T and B cells were weaker, with a predominantly inhibitory influence on DR expression, supporting the notion of a cell-specific effect of LPS on dopaminergic signaling within the immune system. Additionally, our results indicate that hypoxic pretreatment did not alter LPS-induced changes in the dopaminergic pathway. Conclusion: Taken together, this study demonstrates for the first time that systemic LPS administration modulates DR expression in male peripheral immune cells. Further, our in vitro findings suggest that it is the LPS-induced immune response, rather than LPS itself, that drives changes in the dopaminergic pathway in specific immune cell subpopulations. However, further research is needed to elucidate the functional relevance of these findings in clinical contexts.
- Open Access
- 3 February 2025
- Published by Springer Nature in Biology of Sex Differences
- Vol. 16 (1) , 1-18
Acute stimulation of PBMCs drives switch from dopamine-induced anti- to proinflammatory phenotype of monocytes only in women
Several studies report an impact of the neurotransmitter dopamine (DA) on human immune cells, with effects dependent on the immune cell type addressed and their activation status. Another contributing factor appears to be sex, as sex-specific differences in the dopaminergic pathway are described in the neurological context as well as in autoimmune diseases. However, a deeper understanding of these differences in peripheral immune cells remains limited. In this study, we investigated the effects of dopaminergic stimulation on activation and cytokine secretion of peripheral blood mononuclear cells from women and men using flow cytometry, ELISA, and multiplex assays. We found a B cell-driven downregulation in cytokine secretion of monocytes exclusively from women under physiological conditions in vitro. Moreover, B cells from men showed higher dopamine receptor (DR) expression, which was shown to be further increased by sex hormones only in men. In monocytes from women, an acute inflammatory stimulus via CpG combined with dopaminergic stimulation caused a switch to a proinflammatory phenotype, which was less pronounced in men. These novel findings in sex-specific responses to dopaminergic stimulation are crucial for understanding DA’s function in the healthy and activated immune system and provide evidence to treat DA-related pathologies in a sex-specific manner.
- 3 February 2025
- Published by Springer Nature in Biology of Sex Differences
- Vol. 16 (1) , 1-18
Open AccessAcute stimulation of PBMCs drives switch from dopamine-induced anti- to proinflammatory phenotype of monocytes only in women
Several studies report an impact of the neurotransmitter dopamine (DA) on human immune cells, with effects dependent on the immune cell type addressed and their activation status. Another contributing factor appears to be sex, as sex-specific differences in the dopaminergic pathway are described in the neurological context as well as in autoimmune diseases. However, a deeper understanding of these differences in peripheral immune cells remains limited. In this study, we investigated the effects of dopaminergic stimulation on activation and cytokine secretion of peripheral blood mononuclear cells from women and men using flow cytometry, ELISA, and multiplex assays. We found a B cell-driven downregulation in cytokine secretion of monocytes exclusively from women under physiological conditions in vitro. Moreover, B cells from men showed higher dopamine receptor (DR) expression, which was shown to be further increased by sex hormones only in men. In monocytes from women, an acute inflammatory stimulus via CpG combined with dopaminergic stimulation caused a switch to a proinflammatory phenotype, which was less pronounced in men. These novel findings in sex-specific responses to dopaminergic stimulation are crucial for understanding DA’s function in the healthy and activated immune system and provide evidence to treat DA-related pathologies in a sex-specific manner.
- Open Access
Simultaneous Stimulation of Peripheral Blood Mononuclear Cells with CpG ODN2006 and α-IgM Antibodies Leads to Strong Immune Responses in Monocytes Independent of B Cell Activation
CpG ODN2006 is widely used both in vitro and in vivo to achieve B cell activation and has been previously applied in clinical trials as an adjuvant and anti-cancer agent. Recent studies have demonstrated the benefit of combining CpG ODN2006 with α-IgM antibodies to obtain optimal B cell activation in vitro. In this study, we expanded the knowledge of how both agents affect other types of peripheral blood mononuclear cells (PBMCs), thereby highlighting beneficial and potentially unfavorable properties of the combination of CpG ODN2006 and α-IgM when applied beyond isolated B cells. We elucidated the effects of both compounds on mixed PBMCs, as well as on B cell- and monocyte-depleted PBMCs, allowing us to distinguish between direct effects and indirect influences mediated by other interacting immune cells. Flow cytometry was used to measure the expression of surface markers and intracellular cytokines, while ELISA and multiplex assays were performed to determine cytokine secretion. Our results revealed that stimulation of mixed PBMCs with CpG ODN2006 and α-IgM strongly increased cytokine secretion, primarily originating from α-IgM-stimulated monocytes. Monocyte activation was confirmed by increased CD86 and HLA-DR expression and occurred independently of B cells. The high level of monocyte-derived cytokines after α-IgM exposure did not affect B cell activation. However, it represents a rather unfavorable property for clinical applications. In conclusion, α-IgM is a potent inducer of cytokine production in monocytes. Based on our findings we hypothesize that significant side effects on monocytes can occur when using α-IgM to enhance CpG ODN2006’s efficacy on B cells, particularly in clinical settings.
Open AccessSimultaneous Stimulation of Peripheral Blood Mononuclear Cells with CpG ODN2006 and α-IgM Antibodies Leads to Strong Immune Responses in Monocytes Independent of B Cell Activation
CpG ODN2006 is widely used both in vitro and in vivo to achieve B cell activation and has been previously applied in clinical trials as an adjuvant and anti-cancer agent. Recent studies have demonstrated the benefit of combining CpG ODN2006 with α-IgM antibodies to obtain optimal B cell activation in vitro. In this study, we expanded the knowledge of how both agents affect other types of peripheral blood mononuclear cells (PBMCs), thereby highlighting beneficial and potentially unfavorable properties of the combination of CpG ODN2006 and α-IgM when applied beyond isolated B cells. We elucidated the effects of both compounds on mixed PBMCs, as well as on B cell- and monocyte-depleted PBMCs, allowing us to distinguish between direct effects and indirect influences mediated by other interacting immune cells. Flow cytometry was used to measure the expression of surface markers and intracellular cytokines, while ELISA and multiplex assays were performed to determine cytokine secretion. Our results revealed that stimulation of mixed PBMCs with CpG ODN2006 and α-IgM strongly increased cytokine secretion, primarily originating from α-IgM-stimulated monocytes. Monocyte activation was confirmed by increased CD86 and HLA-DR expression and occurred independently of B cells. The high level of monocyte-derived cytokines after α-IgM exposure did not affect B cell activation. However, it represents a rather unfavorable property for clinical applications. In conclusion, α-IgM is a potent inducer of cytokine production in monocytes. Based on our findings we hypothesize that significant side effects on monocytes can occur when using α-IgM to enhance CpG ODN2006’s efficacy on B cells, particularly in clinical settings.
- Open Access
- 30 September 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (12) , e2451299
Chronic stimulation desensitizes β2‐adrenergic receptor responses in natural killer cells
Adrenergic receptors (ARs) are preferentially expressed by innate lymphocytes such as natural killer (NK) cells. Here, we study the effect of epinephrine‐mediated stimulation of the β2‐adrenergic receptor (β2AR) on the function of human NK cells. Epinephrine stimulation inhibited early NK cell signaling events and blocked the function of the integrin LFA‐1. This reduced the adhesion of NK cells to ICAM‐1, explaining how NK cells are mobilized into the peripheral blood upon epinephrine release during acute stress or exercise. Additionally, epinephrine stimulation transiently reduced NK cell degranulation, serial killing, and cytokine production and affected metabolic changes upon NK cell activation via the cAMP‐protein kinase A (PKA) pathway. Repeated exposure to β2AR agonists resulted in the desensitization of the β2AR via a PKA feedback loop‐initiated G‐protein switch. Therefore, acute epinephrine stimulation of chronically β2AR stimulated NK cells no longer resulted in inhibited signaling and reduced LFA‐1 activity. Sustained stimulation by long‐acting β2‐agonists (LABA) not only inhibited NK cell functions but also resulted in desensitization of the β2AR. However, peripheral NK cells from LABA‐treated asthma patients still reacted unchanged to epinephrine stimulation, demonstrating that local LABA administration does not result in detectable systemic effects on NK cells.
- 30 September 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (12) , e2451299
Open AccessChronic stimulation desensitizes β2‐adrenergic receptor responses in natural killer cells
Adrenergic receptors (ARs) are preferentially expressed by innate lymphocytes such as natural killer (NK) cells. Here, we study the effect of epinephrine‐mediated stimulation of the β2‐adrenergic receptor (β2AR) on the function of human NK cells. Epinephrine stimulation inhibited early NK cell signaling events and blocked the function of the integrin LFA‐1. This reduced the adhesion of NK cells to ICAM‐1, explaining how NK cells are mobilized into the peripheral blood upon epinephrine release during acute stress or exercise. Additionally, epinephrine stimulation transiently reduced NK cell degranulation, serial killing, and cytokine production and affected metabolic changes upon NK cell activation via the cAMP‐protein kinase A (PKA) pathway. Repeated exposure to β2AR agonists resulted in the desensitization of the β2AR via a PKA feedback loop‐initiated G‐protein switch. Therefore, acute epinephrine stimulation of chronically β2AR stimulated NK cells no longer resulted in inhibited signaling and reduced LFA‐1 activity. Sustained stimulation by long‐acting β2‐agonists (LABA) not only inhibited NK cell functions but also resulted in desensitization of the β2AR. However, peripheral NK cells from LABA‐treated asthma patients still reacted unchanged to epinephrine stimulation, demonstrating that local LABA administration does not result in detectable systemic effects on NK cells.
- Open Access
- 20 August 2024
- Published by MDPI AG in Preprints.org
Acute Stimulation of PBMCs Drives Switch from Dopamine-Induced Anti- to proinflammatory Phenotype of Monocytes Only in Women
Several studies report an impact of the neurotransmitter dopamine (DA) on human immune cells, with effects dependent on immune cell type addressed and their activation status. Another contributing factor appears to be sex, as sex-specific differences in the dopaminergic pathway are described in the neurological context as well as in autoimmune diseases. However, a deeper understanding of these differences in peripheral immune cells remains limited. In this study, we investigated the effects of dopaminergic stimulation on activation and cytokine secretion of peripheral blood mononuclear cells from women and men using flow cytometry, ELISA and multiplex assay. We found a B cell-driven downregulation in cytokine secretion of monocytes exclusively from women under physiological conditions. Moreover, B cells from men showed higher dopamine receptor (DR) expression, which was shown to be further increased by sex hormones only in men. In monocytes from women, an acute inflammatory stimulus via CpG combined with dopaminergic stimulation caused a switch to a proinflammatory phenotype, which was less pronounced in men. These novel findings in sex-specific responses to dopaminergic stimulation are crucial for understanding DA’s function in the healthy and activated immune system and provide evidence to treat DA-related pathologies in a sex-specific manner.
- 20 August 2024
- Published by MDPI AG in Preprints.org
Open AccessAcute Stimulation of PBMCs Drives Switch from Dopamine-Induced Anti- to proinflammatory Phenotype of Monocytes Only in Women
Several studies report an impact of the neurotransmitter dopamine (DA) on human immune cells, with effects dependent on immune cell type addressed and their activation status. Another contributing factor appears to be sex, as sex-specific differences in the dopaminergic pathway are described in the neurological context as well as in autoimmune diseases. However, a deeper understanding of these differences in peripheral immune cells remains limited. In this study, we investigated the effects of dopaminergic stimulation on activation and cytokine secretion of peripheral blood mononuclear cells from women and men using flow cytometry, ELISA and multiplex assay. We found a B cell-driven downregulation in cytokine secretion of monocytes exclusively from women under physiological conditions. Moreover, B cells from men showed higher dopamine receptor (DR) expression, which was shown to be further increased by sex hormones only in men. In monocytes from women, an acute inflammatory stimulus via CpG combined with dopaminergic stimulation caused a switch to a proinflammatory phenotype, which was less pronounced in men. These novel findings in sex-specific responses to dopaminergic stimulation are crucial for understanding DA’s function in the healthy and activated immune system and provide evidence to treat DA-related pathologies in a sex-specific manner.
- Open Access
- 14 March 2023
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 30 (1) , 81-92
Immediate and Delayed Salivary Cytokine Responses during Repeated Exposures to Cold Pressor Stress
Introduction: Excessive stress is increasingly recognized as an important trigger of many diseases prevalent in modern societies, and monitoring such stress-related effects could aid prevention. The measurement of salivary markers of inflammation is emerging as a promising tool to non-invasively quantify stress’ effects on immune processes in everyday life and thereby detect early aberrations before the manifestation of serious health problems. However, more laboratory-controlled research is needed in order to establish the timescale and determinants of salivary cytokine responses to acute stress. Methods: We repeatedly exposed participants to Cold Pressor Stress Test (CPT) or a control procedure and measured a wide array of salivary cytokines as well as subjective, cardiovascular, and cortisol stress reactions. CPT exposure was repeated every 15 min, 3 times in total, with a duration of 3 min each. Saliva was sampled immediately after the first two exposures as well as in 15-min intervals until 60 min after the onset of the first intervention. Results: We found that many cytokines were detectable in saliva. Specific stress effects were limited to IL-8 and IL-6, however, which decreased immediately or 15 min after stress onset, respectively. Moreover, IL-8 was negatively correlated to cortisol output in the stress but not in the control group. Significant increases were also observed in salivary TNFα and IFNγ; however, these effects were similar under both stress and control conditions. Discussion: Our results show that particular salivary cytokines may be sensitive to immediate effects of acute CPT-induced stress and also highlight the importance of employing control procedures to discern stress effects from unrelated variations in salivary cytokines.
- 14 March 2023
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 30 (1) , 81-92
Open AccessImmediate and Delayed Salivary Cytokine Responses during Repeated Exposures to Cold Pressor Stress
Introduction: Excessive stress is increasingly recognized as an important trigger of many diseases prevalent in modern societies, and monitoring such stress-related effects could aid prevention. The measurement of salivary markers of inflammation is emerging as a promising tool to non-invasively quantify stress’ effects on immune processes in everyday life and thereby detect early aberrations before the manifestation of serious health problems. However, more laboratory-controlled research is needed in order to establish the timescale and determinants of salivary cytokine responses to acute stress. Methods: We repeatedly exposed participants to Cold Pressor Stress Test (CPT) or a control procedure and measured a wide array of salivary cytokines as well as subjective, cardiovascular, and cortisol stress reactions. CPT exposure was repeated every 15 min, 3 times in total, with a duration of 3 min each. Saliva was sampled immediately after the first two exposures as well as in 15-min intervals until 60 min after the onset of the first intervention. Results: We found that many cytokines were detectable in saliva. Specific stress effects were limited to IL-8 and IL-6, however, which decreased immediately or 15 min after stress onset, respectively. Moreover, IL-8 was negatively correlated to cortisol output in the stress but not in the control group. Significant increases were also observed in salivary TNFα and IFNγ; however, these effects were similar under both stress and control conditions. Discussion: Our results show that particular salivary cytokines may be sensitive to immediate effects of acute CPT-induced stress and also highlight the importance of employing control procedures to discern stress effects from unrelated variations in salivary cytokines.
- 4 March 2023
- Published by Springer Nature
- p. 105-133
Catecholamines and Immunomodulation
- Open Access
Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real-time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate-limiting enzyme for dopamine production, and contained dopamine. The activation of D2-like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2-like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2-like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis.
Open AccessModulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real-time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate-limiting enzyme for dopamine production, and contained dopamine. The activation of D2-like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2-like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2-like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis.
- Open Access
- 8 April 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-15
Dopamine receptor 1 expressing B cells exert a proinflammatory role in female patients with rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic rheumatic disease with a clear sex-bias. Recent data indicated a role for dopamine in RA pathogenesis, while dopaminergic pathways can be modulated by estrogens. As defined mechanism of action of dopamine on B cell function in RA are unclear, we aimed to elucidate this, with special focus on sex-differences. Healthy controls (HC, n = 64) and RA patients (n = 61) were recruited. Expression of D1–D5 dopamine receptors (DRs) was investigated by flow cytometry on peripheral blood mononuclear cells (PBMCs). D1-like DRs were stimulated in vitro to assess effects on B cell activation and proliferation. Secretion of cytokines and dopamine content were measured by ELISA. All DRs were expressed on PBMCs of HC and RA patients. Dopamine content in PBMCs, and frequency of D1DR expressing B cells were significantly higher in RA females (p < 0.001). Expression of D1DR on RA B cells correlated positively with disease duration and severity only in women. Combined B cell and D1-like DR stimulation induced higher IL-8 and CCL-3 secretion from PBMCs of female RA patients compared to HC. These results indicate sex-specific differences in dopaminergic pathway in RA, with a proinflammatory feature of the D1DR pathway in women.
- 8 April 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-15
Open AccessDopamine receptor 1 expressing B cells exert a proinflammatory role in female patients with rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic rheumatic disease with a clear sex-bias. Recent data indicated a role for dopamine in RA pathogenesis, while dopaminergic pathways can be modulated by estrogens. As defined mechanism of action of dopamine on B cell function in RA are unclear, we aimed to elucidate this, with special focus on sex-differences. Healthy controls (HC, n = 64) and RA patients (n = 61) were recruited. Expression of D1–D5 dopamine receptors (DRs) was investigated by flow cytometry on peripheral blood mononuclear cells (PBMCs). D1-like DRs were stimulated in vitro to assess effects on B cell activation and proliferation. Secretion of cytokines and dopamine content were measured by ELISA. All DRs were expressed on PBMCs of HC and RA patients. Dopamine content in PBMCs, and frequency of D1DR expressing B cells were significantly higher in RA females (p < 0.001). Expression of D1DR on RA B cells correlated positively with disease duration and severity only in women. Combined B cell and D1-like DR stimulation induced higher IL-8 and CCL-3 secretion from PBMCs of female RA patients compared to HC. These results indicate sex-specific differences in dopaminergic pathway in RA, with a proinflammatory feature of the D1DR pathway in women.